Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Albany Molecular Research, Inc.    AMRI

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Albany Molecular Research, Inc. : AMRI Hires Senior Manager to Oversee Facilities at Burlington Aseptic Fill Operations

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/27/2012 | 02:05pm CET

ALBANY, N.Y., March 27, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today another key addition to its management team at its aseptic fill and finish facility in Burlington, Mass. Stephen Rossmeisl has joined the company as Senior Facilities Manager, reporting to Eric Peterson, Director of Manufacturing. Mr. Rossmeisl's more than 15 years of plant engineering and facilities management experience will provide the expertise and leadership necessary to effectively plan and implement facility maintenance programs, environmental monitoring compliance systems and expansion projects.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

Combined with previously announced recent senior leadership changes at Burlington, Mr. Rossmeisl's addition further demonstrates AMRI's commitment to providing industry leading aseptic services with uncompromising quality to the company's growing client base.

AMRI's Burlington, Mass. facility offers clients innovative aseptic formulation and filling services for pre-clinical through small-volume, commercial-scale production of liquid-filled parenterals, biologics and medical devices in vials, syringes and other custom containers.

Mr. Rossmeisl has worked for large pharmaceutical companies performing all phases of construction, design, and commissioning. He comes to AMRI from his most recent role as the Associate Director of Facilities Operations for Shire HGT in Lexington, Mass., where in addition to maintenance oversight he served as the lead project engineer for significant laboratory and office expansion projects. Mr. Rossmeisl's experience with critical cleanroom equipment, utilities and systems will strengthen AMRI's ability to meet the growing needs of its customers as the level of activity of new business at Burlington continues on a path to a return to previously robust levels.

"Steve brings extensive knowledge and experience in supporting critical cleanroom infrastructure, equipment and GMP operations," said Steven R. Hagen, Ph.D., Vice President, Pharmaceutical Development and Manufacturing, AMRI. "Steve will be instrumental in ensuring compliance and overall effectiveness of the facility's preventive maintenance program and critical environmental monitoring systems, and will lead the planning, oversight and execution of future expansion projects."

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization with more than twenty years experience providing customers fully integrated drug discovery, development, and manufacturing services. AMRI supplies a broad range of services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of API and drug product for existing and experimental new drugs. With locations in the United States, Europe, and Asia, AMRI maintains geographic proximity and flexible cost models. AMRI has also historically leveraged its drug-discovery expertise to execute on several internal drug discovery programs, which have progressed to the development candidate stage and in some cases into Phase I clinical development. AMRI has successfully partnered certain programs and is actively seeking to out-license its remaining programs to strategic partners for further development.

SOURCE AMRI

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALBANY MOLECULAR RESEARCH,
01/19 ALBANY MOLECULAR RESEARCH : Whitehouse Labs Increases Focus and Expertise In Ext..
01/18 ALBANY MOLECULAR RESEARCH : Whitehouse Labs Increases Focus and Expertise In Ext..
2016 ALBANY MOLECULAR RESEARCH, INC. (NAS : AMRI) Files An 8-K Other Events
2016 ALBANY MOLECULAR RESEARCH INC : Other Events (form 8-K)
2016 ALBANY MOLECULAR RESEARCH : UAlbany Health Sciences campus awarded $4M grant
2016 ALBANY MOLECULAR RESEARCH : Assigned Patent
2016 AMRI : to Present Two Posters at AAPS 2016
2016 Amri announces third quarter 2016 results
2016 ALBANY MOLECULAR RESEARCH : Management's Discussion and Analysis of Financial Co..
2016 ALBANY MOLECULAR RESEARCH INC : Results of Operations and Financial Condition, F..
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/11 Albany Molecular Research (AMRI) Presents At J.P. Morgan Healthcare Conferenc..
2016 AMRI closes supply deal with Shire
2016 Albany Molecular Research, Inc. 2016 Q3 - Results - Earnings Call Slides
2016 Albany Molecular Research's (AMRI) CEO William Marth on Q3 2016 Results - Ear..
2016 Albany Molecular beats by $0.04, misses on revenue